CDC Survey Finds GLP-1 Users Skipping Doses
Nearly half the adults who used a GLP-1 drug changed how they took it, and it's cost that drove the change hardest for the youngest users.
The drugs work as prescribed. It's real life that keeps breaking the schedule.
About one in ten American adults used a GLP-1 drug in the past year, and 44 percent of them didn't take it as prescribed.
The figures come from a CDC survey published in MMWR on November 12. The agency's Rapid Surveys System questioned 8,118 adults in July and August 2025, and 976 of them had used a GLP-1 drug in the past year. Use reached 9.8 percent of adults, and it included about half of adults with diabetes.
Skipping doses was the most common change, at 28 percent of users. Among the users who changed how they took the drug, 38 percent named cost and 36 percent named availability. Age split the answers hard. Users aged 18 to 39 changed their use at 54 percent, against 30 percent for users 65 and older, and it's cost that drove 58 percent of the younger group's changes against 20 percent for the older group.
Compounded versions run through the results. About 22.6 percent of users took a compounded GLP-1, and 8.8 percent didn't know whether theirs was compounded. The CDC notes compounded products aren't reviewed by the FDA for safety, effectiveness or quality, and they might carry added ingredients nobody regulated. Compounded users changed their use at 62 percent, against 36 percent for everyone else.
The pattern points at price, not forgetfulness. Women used compounded versions at 27.3 percent against 14.8 percent for men, and private insurance holders used them at 25.9 percent against 12.5 percent for other coverage. The people stretching doses and buying compounded versions are largely the people paying the most out of pocket, and they're stretching because the full-price version doesn't fit the month.
The conversation.
Loading comments…
A little more perspective.
Reading is free. Verified members can comment and reply for $2 a month.